Journal Mobile Options
Table of Contents
Vol. 196, No. 2, 1998
Issue release date: 1998
Dermatology 1998;196:237–241
(DOI:10.1159/000017881)

Fluconazole in the Treatment of Tinea corporis and Tinea cruris

Stary A. · Sarnow E.
aOutpatient Clinic for Fungal Infections, Vienna, Austria; bClinical Research Department, Pfizer GmbH, Karlsruhe, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Results of topical dermatomycosis treatment are often unsatisfactory, particularly in patients with extended or multiple infection sites. Objective: Given the high fluconazole concentrations attainable in the stratum corneum and the long elimination half-life of fluconazole, we investigated whether efficacy is satisfactory when using fluconazole at once weekly doses of 150 mg. Methods: In an open, noncomparative study, tinea corporis and cruris patients were treated with once weekly fluconazole 150 mg over 2–4 weeks. Clinical (pruritus, erythema, scaling, burning/pain, vesiculation) and mycologic (culture and microscopy) assessments were performed before treatment, at weekly intervals until the end of treatment and 3 weeks after treatment. All adverse events were recorded. Results: The total severity scores of clinical symptoms were reduced from 7.1 before to 1.5 after treatment (p = 0.001, n = 100 patients). Seven patients experienced adverse events. Conclusions: Fluconazole 150 mg once weekly for 2–4 weeks is an efficacious and safe regimen in the treatment of tinea corporis and cruris.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Brammer KW, Farrow PR, Faulkner JK: Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990;12(suppl 3):318–326.
  2. Wildfeuer A, Laufen H, Pfaff G, Zimmermann T, Lach P: Bioverfügbarkeit von Fluconazol in der Haut nach oraler Medikation. Mycoses 1992;35(suppl):65–68.
  3. Tschechne B, Brunkhorst U, Ruhnke M, Trautmann M, Dempe S, Deicher H: Fluconazol in der Therapie der Candidose des Mund-Rachen-Raumes bei Patienten mit HIV-Infektion. Med Klin 1991;86:508–511.

    External Resources

  4. Stoehr A, Plettenberg A, Begemann F, Heise W, Höffken G: Therapie der Soorösophagitis mit Fluconazol bei AIDS-Patienten. Chemother J 1992;1: 116–119.
  5. Just-Nübling G, Gentschew G, Döhle M, Böttinger C, Helm EB, Stille W: Fluconazole in the treatment of oropharyngeal candidosis in HIV-positive patients. Mycoses 1990;33: 435–440.

    External Resources

  6. Kujath P, Lerch K, Kochendörfer P, Boos C: Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. Infection 1993;21:376–382.

    External Resources

  7. Ikemoto H: A clinical study of fluconazole for the treatment of deep mycoses. Diagn Microbiol Infect Dis 1989;12:239–247.

    External Resources

  8. De Cuyper C, Amblard P, Austad J, Bazex J, Bohmann P, de Bersaques J, Garrel JB, Gjorud M, Grosshans E, Hanssen L, Hjorth N, Holzmann H, Jeanpierre G, Johnsen J, Langeland J, Langeland B, Lauret P, Mackie RM, Meinicke K, Mork N, Ortonne JP, Puissant A, Rosman N, Sondergaard J, Stuttgen G, Svejgaard E, Thorvaldsen J: Noncomparative study of fluconazole in the treatment of patients with common fungal infections of the skin. Int J Dermatol 1992;31(suppl 2):17–20.
  9. Naeyaert J, de Bersaques J, de Cuyper C, Hindryckx Ph, van Landuyt H, Gordts B: Fluconazole (UK-49,858): A novel oral antifungal, in the tratment of fungal skin infections. Results of an open study in 43 patients; in Fromtling RA, Prous JR (eds): Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. JR Prous Science Publishers, SA, USA. Science Publications, 1987, pp 157–161.
  10. Lospalluti F, Barile A, Pantaleo K, Conese M, Puglisi Guerra A, Lo Re M, D’Amico G, Barbieri G: Valutazione comparativa di fluconazolo 50 mg e 100 mg vs intraconazolo 100 mg nel trattamento delle epidermomicosi. Clinica Ter 1993;144:129–138.
  11. Haneke E: Pharmacokinetic evaluation of fluconazole in plasma, epidermis and blister fluid. Int J Dermatol 1992;31(suppl 2):3–5.
  12. Hay J: Pharmacokinetic evaluation of fluconazole in skin and nails. Int J Dermatol 1992;31 (suppl 2):6–7.
  13. Faergemann J, Laufen H: Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat. Clin Exp Dermatol 1993;18:102–106.
  14. Montero-Gei F, Perera A: Therapy with fluconazole for tinea corporis, tinea cruris and tinea pedis. Clin Infect Dis 1992;14(suppl 1): 77–81.
  15. Suchil P, Gei FM, Robles M, Perera-Ramirez A, Welsh O, Male O: Once-weekly oral dosis of fluconazole 150 mg in the treatment of tinea corporis/cruris and cutaneous candidiasis. Clin Exp Dermatol 1992;17:397–401.
  16. De Cuyper C, de Bersaques J, Delescluse J, Grigoriu D, Haneke E, Hay RJ, Luger A, Menke HE, Sondergaard J, Hentzer B: Evaluation of four oral daily doses of fluconazole in the treatment of cutaneous mycoses. Int J Dermatol 1992;31(suppl 2):8–11.
  17. Fischbein A, Haneke E, Lacner K, Male O, Mohn R, Muller H, O’Connolly M, Tronnier H, Vogel F: Comparative evaluation of oral fluconazole and oral ketokonazole in the treatment of fungal infections of the skin. Int J Dermatol 1992;31(suppl 2):12–16.
  18. De Bersaque J, Bjerke R, Borelli S, Brown AC, Cottenot F, Daniel F, Dupont B, Gschnait F, Heenen M, Jegasothy BV, Kramer M, Lapière C, Neldner KH, Olsen EA, Parish LC, Privat Y, Savin RC, Schnabel P, Shubert B, Stenvold SE, Svindland HB, Tschen E, Vickers CFH, Wallach D, Wade AG, Zaias N: Comparison of oral fluconazole and topical clotrimazole in the treatment of fungal infections of the skin: European and American experience. Int J Dermatol 1992;31(suppl 2):21–26.
  19. Stengel M, Robles-Soto R, Galimberti P, Suchil P: Fluconazole versus ketoconazole in the treatment of dermatophytoses and cutaneous candidiasis. Int J Dermatol 1994;33: 726–729.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50